CorTec’s Brain Interchange™ Accepted into FDA Total Product Life Cycle Advisory Program
CorTec GmbH has been accepted into the FDA’s Total Product Life Cycle Advisory Program for its Brain Interchange™ system, recognized as a priority innovation in stroke motor rehabilitation. This acceptance follows the FDA Breakthrough Device Designation. The clinical trial for the device has successfully implanted three patients, marking significant progress in its development. The TAP Program provides structured support for navigating approval and reimbursement, enhancing CorTec’s position in the neurotechnology field.
Third patient successfully implanted at Harborview Medical Center as NIH-funded stroke trial advances
Third patient successfully implanted at Harborview Medical Center as NIH-funded stroke trial advances